- |||||||||| Review, Journal: Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review. (Pubmed Central) - Jan 23, 2024
On the other hand, dinalbuphine sebacate (DNS; semi-synthetic mu partial antagonist and kappa agonist), dual enkephalinase inhibitors (STR-324, PL37, and PL265), and endomorphin-1 analog (CYT-1010) have shown good efficacy in preclinical studies with future plans for clinical trials. Rather than relying solely on mu-opioid receptor agonism to relieve pain and risk opioid-related adverse events (ORAEs), novel opioids make use of alternative mechanisms of action to treat pain while maintaining a safer side-effect profile, such as lower incidence of nausea, vomiting, sedation, and respiratory depression as well as reduced abuse potential.
- |||||||||| STR-324 / ArchiMed
Review, Journal: Enhancing Opiorphin's Metabolic Stability and Preserving its Potent Analgesic Effect: A Systematic Review. (Pubmed Central) - Nov 7, 2023 Rather than relying solely on mu-opioid receptor agonism to relieve pain and risk opioid-related adverse events (ORAEs), novel opioids make use of alternative mechanisms of action to treat pain while maintaining a safer side-effect profile, such as lower incidence of nausea, vomiting, sedation, and respiratory depression as well as reduced abuse potential. This paper presents the first systematic review discussing opiorphin and opiorphin analogs and identifies the most promising candidates for future research.
- |||||||||| STR-324 / Stragen
Trial completion date, Trial primary completion date: Dose Finding Study of STR-324 (clinicaltrials.gov) - Jul 13, 2021 P2, N=118, Recruiting, No clear effects on nociceptive thresholds or other pharmacodynamic measures were observed. Trial completion date: Jul 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Jan 2022
- |||||||||| STR-324 / Stragen
Enrollment open: Dose Finding Study of STR-324 (clinicaltrials.gov) - Mar 18, 2021 P2, N=116, Recruiting, Trial completion date: Jul 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Jan 2022 Not yet recruiting --> Recruiting
|